-
2023-508956-20-00
5
2020-03-12
Hidradenitis suppurativa
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2022-501257-36-00
9
2015-03-19
Treatment of advanced melanoma, or advanced, relapsed or
refractory PD
-
2023-503479-79-00
4
2011-06-17
Metastatic Cancer
-
2026-525823-26-00
2
2026-04-25
No medical condition.
-
2025-522627-10-00
2
2026-04-20
No medical condition.
-
2025-522624-27-00
2
2026-04-15
No medical condition.
-
2025-521918-26-00
4
2026-02-11
HIV Infections
-
2023-506146-23-00
4
2025-11-17
Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder
-
2025-520809-12-00
10
2025-10-16
Diabetic Macular Edema
-
2024-516473-72-00
5
2025-07-31
Multifocal Motor Neuropathy
-
2024-519773-19-00
5
2025-07-31
Gastroesophageal Junction Adenocarcinoma
-
2024-520109-37-00
4
2025-07-09
PMM2-CDG
-
2022-503001-38-01
5
2025-07-08
HR-positive HER-2- negative Breast Cancer
-
2024-513282-39-00
5
2025-05-28
Hidradenitis Suppurativa (HS)
-
2024-513621-23-00
5
2025-04-18
Advanced/metastatic non-small cell lung cancer (NSCLC)
-
2024-514942-35-00
3
2025-04-11
Type 1 interferonopathies
-
2024-514133-38-00
5
2025-03-19
Ocular Myasthenia Gravis
-
2024-512946-41-00
5
2025-03-05
Menstrual Migraine
-
2024-512998-27-00
5
2025-02-21
Non-Small Cell Lung Cancer
-
2024-518343-38-00
5
2025-02-12
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-505394-32-00
5
2025-02-06
chronic graft versus host disease
-
2022-502878-16-00
5
2025-01-23
Acute ischemic strokes with incomplete reperfusion